BC Extra | Aug 15, 2019
Clinical News

At last, a win for terlipressin -- and Mallinckrodt

Ten years after being rebuffed by FDA and with a failed Phase III trial squeezed in between, Mallinckrodt’s terlipressin finally hit the mark in treating patients with an acute form of kidney failure. On Thursday,...
BC Week In Review | Nov 9, 2015
Clinical News

INOmax regulatory update

Mallinckrodt said Australia and Japan approved INOmax nitric oxide (NO) for inhalation for pulmonary hypertension (PH) in conjunction with heart surgery. The product is approved in both countries for hypoxic respiratory failure (HRF). In Australia,...
BioCentury | Sep 14, 2015
Finance

Periodic piece

About a decade after an Arch Venture-led syndicate formed Ikaria Inc. to develop elemental reducing agents for critical care, the firm is going back for round two with the technology. Although the assets have been...
BC Week In Review | Mar 9, 2015
Company News

Mallinckrodt, Ikaria deal

Mallinckrodt will acquire Ikaria for $2.3 billion from an investor group led by private equity firm Madison Dearborn Partners. Ikaria markets INOmax inhaled nitric oxide to treat hypoxic respiratory failure associated with pulmonary hypertension in...
BC Extra | Mar 6, 2015
Company News

Mallinckrodt to acquire Ikaria for $2.3B

Mallinckrodt plc (NYSE:MNK) will acquire Ikaria Inc. (Hampton, N.J.) for $2.3 billion from an investor group led by private equity firm Madison Dearborn Partners. Ikaria markets INOmax inhaled nitric oxide to treat hypoxic respiratory failure...
BC Week In Review | Nov 24, 2014
Company News

Ikaria, Lee’s Pharmaceutical Holdings Ltd. deal

Ikaria granted Lee’s rights to INOmax nitric oxide in China, including Hong Kong and Macau, and Taiwan. The inhaled nitric oxide to treat hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants...
BC Extra | Nov 20, 2014
Company News

Lee's gains China rights to Ikaria's INOmax

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) received rights from Ikaria Inc. (Hampton, N.J.) to INOmax in China, Hong Kong, Macau and Taiwan. The inhaled nitric oxide to treat hypoxic respiratory failure associated with pulmonary hypertension in...
BC Week In Review | Jan 6, 2014
Company News

Ikaria, Madison Dearborn Partners deal

On Dec. 24, 2013, private equity firm Madison Dearborn said it will acquire the majority stake in the commercial business of Ikaria in a deal the parties said values the business at about $1.6 billion....
BC Extra | Dec 27, 2013
Company News

PE firm acquiring majority stake of Ikaria's commercial business

Private equity firm Madison Dearborn Partners will acquire the majority stake in the commercial business of Ikaria Inc. (Hampton, N.J.) in a deal the parties said values the business at about $1.6 billion. Existing Ikaria...
BioCentury | Oct 14, 2013
Finance

Gas money

Gas money Critical care company Ikaria Inc. is reportedly exploring a $2 billion buyout just three years after withdrawing an IPO that would have valued it at about $500 million. A takeout would be icing...
Items per page:
1 - 10 of 31